CHRS

Q: What is the price of Coherus BioSciences (CHRS) today?

The price of Coherus BioSciences (CHRS) today is R$ 6,12, with a variation of -22.07% compared to the last year. The price of Coherus BioSciences (CHRS) started the year trading around R$ 7,48 and today it is at R$ 6,12. Follow the real-time price chart, the historical price of Coherus BioSciences (CHRS), and stock data from Ibovespa and international markets.

Q: When does Coherus BioSciences (CHRS) pay dividends?

Coherus BioSciences (CHRS) did not distribute dividends in the last year.

Q: Coherus BioSciences (CHRS) is it worth it?

Currently, Coherus BioSciences (CHRS) is priced at R$ 6,12, with a P/E of 0,79%, representing a deviation of -0,27% from its historical average P/E. In the last year, the stock showed a variation of -22.07% in its price and distributed R$ 0,00 in dividends, resulting in a Dividend Yield of 0,00%. The total shareholder return was -22,07%.It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

Q: How to buy shares of Coherus BioSciences (CHRS)?

Investing in shares of Coherus BioSciences (CHRS) can be done in two ways: by buying the stock abroad or the BDR in Brazil (if available). The stock is the original stock, traded on international exchanges. By buying it, you invest with money outside Brazil, which brings greater geographical and currency diversification.The BDR is a receipt for that stock, traded on the B3 with reais, through a brazilian brokerage. Although the money remains in Brazil, the BDR still offers diversification, as it represents a foreign company and is linked to the dollar.

Q: How much do 100 shares of Coherus BioSciences (CHRS) yield today?

The yield of Coherus BioSciences (CHRS) was 8,65% in the last month, -22,07% in the last year and -94,17% in the last 5 years (already considering appreciation and dividends).In the last 12 months, the company paid a total of R$ 0,00 in dividends, um Dividend Yield de 0,00%.If you wanted to buy 100 shares of Coherus BioSciences (CHRS) today, the total investment would be based on the current price of R$ 6,12.If past performance were to repeat, the return on your investment would be:In 1 year: R$ 477,29In 5 years: R$ 35,71In 10 years: 25,05It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

Coherus BioSciences Inc.

Price

US$ 1,13

variation (12m)

-22,07%

p/l

0,79

p/vp

1,19

DIVIDEND YIELD

0,00%

quote CHRS

BVMF

CHRS

If you had invested

year ago

6 months

1 year

5 years

10 years

today you would have

today you would have:

*The figure considers the reinvestment of dividends.

profitability of CHRS

1 month

3 months

1 year

2 years

5 years

10 years

profitability

1 month

8,65%

3 months

41,41%

1 year

-22,07%

2 years

-75,96%

5 years

-94,17%

10 years

-95,91%

real profitability

profitability minus inflation.

1 month

8,65%

3 months

40,71%

1 year

-25,95%

2 years

-78,09%

5 years

-95,74%

10 years

-97,58%

Indicators CHRS

check out the fundamentals of Coherus BioSciences shares

P/L

0,79

Sector: -3,27 Industry: -3,27

P/SALES (PSR)

1,00

Sector: -3,77 Industry: -3,77

P/VP

1,19

Sector: 1,74 Industry: 1,74

DIVIDEND YIELD (DY)

0,00%

Sector: - Industry: -

ROA

40,90%

Sector: -63,50% Industry: -63,50%

ROE

150,00%

Sector: -67,23% Industry: -67,23%

ROIC

-199,52%

Sector: -2.087,74% Industry: -2.087,74%

Net Margin

100,00%

Sector: -43,34% Industry: -43,34%

GROSS MARGIN

57,53%

Sector: 40,50% Industry: 40,50%

OPERATING MARGIN

-97,77%

Sector: -43,21% Industry: -43,21%

P/EBITDA

-1,07

Sector: -3,13 Industry: -3,13

P/EBIT

-1,03

Sector: -3,41 Industry: -3,41

P/ASSETS

0,32

Sector: 1,29 Industry: 1,29

VPA

1,03

Sector: 1,80 Industry: 1,80

LPA

1,55

Sector: -2,09 Industry: -2,09

EQUITY / ASSETS

0,27

Sector: 0,42 Industry: 0,42

CAGR REVENUES 5 YEARS

-21,40%

Sector: - Industry: -

CAGR PROFITS 5 YEARS

6,33%

Sector: - Industry: -

FAIR PRICE OF Coherus BioSciences ASSETS ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Price

The Fair Price formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffet's mentor.

Current price

US$ 1,13

Fair Price

US$ 0,00

Upside Potencial de rentabilidade.

430,39%

See Graham's ranking

Because it considers equity value in its calculation, the formula does not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

CHRS indicators history

DRAG THE FRAME TO SEE MORE DATA

comparator of Stocks

DRAG THE FRAME TO SEE MORE DATA

	p/l	p/vp	ROE	dy	market value	Net Margin
JNJ	19,04	5,50	28,88%	2,80%	US$ 431,37 B	25,00%
PFE	13,45	1,62	12,08%	6,68%	US$ 144,63 B	16,84%
ABBV	79,66	228,58	286,94%	3,38%	US$ 334,19 B	7,31%
NVO	15,51	9,75	62,86%	2,83%	US$ 253,39 B	35,63%
MRK	13,05	4,36	33,44%	3,75%	US$ 214,13 B	25,79%
BMY	19,31	5,58	28,87%	5,13%	US$ 97,52 B	10,58%
GILD	22,64	7,29	32,21%	2,72%	US$ 142,89 B	21,87%
AZN	30,26	5,60	18,51%	1,91%	US$ 251,01 B	14,68%
ZTS	26,68	14,00	52,48%	1,19%	US$ 69,70 B	27,83%
HALO	15,59	26,12	167,47%	0,00%	US$ 8,69 B	47,28%
REGN	13,88	2,07	14,89%	0,30%	US$ 61,90 B	31,37%
AMGN	23,87	21,27	89,11%	3,15%	US$ 158,02 B	18,96%
VRTX	27,92	5,91	21,18%	0,00%	US$ 101,55 B	31,86%
ADMA	20,53	10,77	52,45%	0,00%	US$ 4,29 B	44,06%
MCK	27,24	-99,86	-366,63%	0,41%	US$ 86,18 B	0,84%
BIIB	13,38	1,16	8,68%	0,00%	US$ 20,48 B	15,31%
CAH	22,58	-13,38	-59,26%	1,37%	US$ 35,25 B	0,70%

comparison of CHRS with indexes

If you had invested (change) 2 years a year ago, today you would have

R$ 1.000,00 in PETR4 you would have R$ 2.294,60

R$ 1.000,00 in LEVE3 you would have R$ 5.240,60

*The value considers the reinvestment of dividends.

dividend history CHRS dividend history

Current DY: 0,00%

5-year average DY: 0,00%

no dividend paid in the period.

ABOUT THE COMPANY Coherus BioSciences

Coherus BioSciences Inc.

Average user rating I10

4.0 (1 people)

Estados Unidos

15 years

Foundation: 2010

2014

Year of debut on the stock exchange - 11 years

291

Employees

The Company Coherus BioSciences Inc. (Estados Unidos), is listed on Nasdaq with a market value of $ 142,68 Milhões, having a net worth of $ 119,83 Milhões.

With a total of 291 employees, the company is listed in the sector of Cuidados de saúde and categorized in industry of Biotecnologia.

In the last 12 months the Company had a revenue of $ 142,76 Milhões, which generated a profit in the amount of $ 179,75 Milhões.

As for its main indicators, the Company has a P/E ratio of 0,79, a P/B ratio of 1,19 and in the last 12 months the Company did not pay dividends.

The Company is traded through the ticker CHRS.

Market value

US$ 142,68 Milhões

Net worth

US$ 119,83 Milhões

US$ 119.830.000,00

Assets

US$ 439,46 Milhões

US$ 439.460.000,00

Total Number of Shares

116,00 Milhões

116.000.000

Average Daily Trading Volume

US$ 1,37 Million

US$ 1.368.744,06

Sector

Cuidados de saúde

Industry

Biotecnologia

CHRS

CHRS revenue and profits

CHRS results

DRAG THE FRAME TO SEE MORE DATA

CHRS cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

US$ - -0,00% (12M)

P/L

0,00

0,00%

ROE

-893,55%

P/VP

0,00

MCK - McKesson

US$ 680,52 24,27% (12M)

P/L

27,24

0,41%

ROE

-366,63%

P/VP

-99,86

CAH - Cardinal Health

US$ 147,49 36,56% (12M)

P/L

22,58

1,37%

ROE

-59,26%

P/VP

-13,38

JNJ - Johnson & Johnson

US$ 176,49 12,66% (12M)

P/L

19,04

2,80%

ROE

28,88%

P/VP

5,50

MRK - Merck & Co.

US$ 84,99 --23,85% (12M)

P/L

13,05

3,75%

ROE

33,44%

P/VP

4,36

PFE - Pfizer

US$ 24,92 --5,92% (12M)

P/L

13,45

6,68%

ROE

12,08%

P/VP

1,62

AZN - AstraZeneca

US$ 80,05 --5,68% (12M)

P/L

30,26

1,91%

ROE

18,51%

P/VP

5,60

ABBV - AbbVie

US$ 208,36 10,15% (12M)

P/L

79,66

3,38%

ROE

286,94%

P/VP

228,58

BFRA - Biofrontera

US$ - -0,00% (12 M)

P/L

0,00

0,00%

ROE

-893,55%

P/VP

0,00

MCK - McKesson

US$ 680,52 24,27% (12 M)

P/L

27,24

0,41%

ROE

-366,63%

P/VP

-99,86

CAH - Cardinal Health

US$ 147,49 36,56% (12 M)

P/L

22,58

1,37%

ROE

-59,26%

P/VP

-13,38

JNJ - Johnson & Johnson

US$ 176,49 12,66% (12 M)

P/L

19,04

2,80%

ROE

28,88%

P/VP

5,50

MRK - Merck & Co.

US$ 84,99 --23,85% (12 M)

P/L

13,05

3,75%

ROE

33,44%

P/VP

4,36

PFE - Pfizer

US$ 24,92 --5,92% (12 M)

P/L

13,45

6,68%

ROE

12,08%

P/VP

1,62

AZN - AstraZeneca

US$ 80,05 --5,68% (12 M)

P/L

30,26

1,91%

ROE

18,51%

P/VP

5,60

ABBV - AbbVie

US$ 208,36 10,15% (12 M)

P/L

79,66

3,38%

ROE

286,94%

P/VP

228,58

Common Questions

What is the price of Coherus BioSciences (CHRS) today?

The price of Coherus BioSciences (CHRS) today is R$ 6,12, with a variation of -22.07% compared to the last year. The price of Coherus BioSciences (CHRS) started the year trading around R$ 7,48 and today it is at R$ 6,12. Follow the real-time price chart, the historical price of Coherus BioSciences (CHRS), and stock data from Ibovespa and international markets.

When does Coherus BioSciences (CHRS) pay dividends?

Coherus BioSciences (CHRS) did not distribute dividends in the last year.

Coherus BioSciences (CHRS) is it worth it?

Currently, Coherus BioSciences (CHRS) is priced at R$ 6,12, with a P/E of 0,79%, representing a deviation of -0,27% from its historical average P/E. In the last year, the stock showed a variation of -22.07% in its price and distributed R$ 0,00 in dividends, resulting in a Dividend Yield of 0,00%. The total shareholder return was -22,07%.

It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

How to buy shares of Coherus BioSciences (CHRS)?

Investing in shares of Coherus BioSciences (CHRS) can be done in two ways: by buying the stock abroad or the BDR in Brazil (if available). The stock is the original stock, traded on international exchanges. By buying it, you invest with money outside Brazil, which brings greater geographical and currency diversification.

The BDR is a receipt for that stock, traded on the B3 with reais, through a brazilian brokerage. Although the money remains in Brazil, the BDR still offers diversification, as it represents a foreign company and is linked to the dollar.

How much do 100 shares of Coherus BioSciences (CHRS) yield today?

The yield of Coherus BioSciences (CHRS) was 8,65% in the last month, -22,07% in the last year and -94,17% in the last 5 years (already considering appreciation and dividends).

In the last 12 months, the company paid a total of R$ 0,00 in dividends, um Dividend Yield de 0,00%.

If you wanted to buy 100 shares of Coherus BioSciences (CHRS) today, the total investment would be based on the current price of R$ 6,12.

If past performance were to repeat, the return on your investment would be:

In 1 year: R$ 477,29
In 5 years: R$ 35,71
In 10 years: 25,05

It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

CHRS

Coherus BioSciences Inc.

Price

variation (12m)

p/l

p/vp

DIVIDEND YIELD

profitability of CHRS

check out the fundamentals of Coherus BioSciences shares

P/L

P/SALES (PSR)

P/VP

DIVIDEND YIELD (DY)

ROA

ROE

ROIC

Net Margin

GROSS MARGIN

OPERATING MARGIN

P/EBITDA

P/EBIT

P/ASSETS

VPA

LPA

EQUITY / ASSETS

CAGR REVENUES 5 YEARS

CAGR PROFITS 5 YEARS

Graham's Fair Price

If you had invested (change) 2 years a year ago, today you would have

Current DY: 0,00%

5-year average DY: 0,00%

ABOUT THE COMPANY Coherus BioSciences

Coherus BioSciences Inc.

Estados Unidos

15 years

2014

291

PROFIT X PRICE CHRS

CHRS results

CHRS cash flow

evolution of assets - CHRS

CHRS balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

MRK - Merck & Co.

PFE - Pfizer

AZN - AstraZeneca

ABBV - AbbVie

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

MRK - Merck & Co.

PFE - Pfizer

AZN - AstraZeneca

ABBV - AbbVie

Common Questions

Tudo que o investidor precisa em um só lugar

Pague 2, Leve 3

Anual

Valor total R$ 238,80